Jazz Pharmaceuticals plc (JAZZ) Discusses FDA Approval and Commercial Launch of ZIIHERA for First-Line HER2-Positive GEA Transcript

SA Transcripts 162K Followers Follow Jazz Pharmaceuticals plc ( JAZZ ) Discusses FDA Approval and Commercial Launch of ZIIHERA for First-Line HER2-Positive GEA August 25, 2026 4:30 PM EDT Company Participants John Bluth - Head of Investor Relations Robert Iannone - Executive VP, Chief Medical Officer and Global Head of Research & Development Chumi Khurana Samantha Pearce - Executive VP & Chief Commercial Officer Conference Call Participants Jessica Fye - JPMorgan Chase & Co, Research Division Marc Goodman - Leerink Partners LLC, Research Division Gregory Renza - Truist Securities, Inc., Research Division Annabel Samimy - Stifel, Nicolaus & Company, Incorporated, Research Division Jason Gerberry - BofA Securities, Research Division Leonid Timashev - RBC Capital Markets, Research Division Alexandra von Riesemann - Piper Sandler & Co., Research Division Gary Nachman - Canaccord Genuity Corp., Research Division Sean Laaman - Morgan Stanley, Research Division David Hoang - Deutsche Bank AG, Research Division Joseph Thome - TD Cowen, Research Division Presentation Operator Good day, and thank you for standing by. Welcome to the Ziihera GEA Investor Webcast Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. I would now like to turn the call over to your speaker for today, Rob -- John Bluth, Head of Investor Relations. Please go ahead. John Bluth Head of Investor Relations Thank you, operator, and thank you all for joining us. We're excited to discuss the FDA approval in U.S. commercial launch of Ziihera in first-line HER2-positive metastatic gastroesophageal adenocarcinoma, or GEA. The slide presentation accompanying this webcastis available on the Investors section of our website, and you can also reference the press release we issued regarding the FDA approval of Ziihera. Also on our website, you can find a link to the approved label. On Slide 2, I'd like to remind you that today's webcast includes forward-looking statements, such as those related to our future financial and operating results, growth potential and anticipated